sotorasib - Robuta Search

https://www.biospace.com/amgen-s-sotorasib-granted-breakthrough-therapy-designation-for-advanced-or-metastatic-non-small-cell-lung-cancer-patients-with-kras-g12c-mutation Amgen's Sotorasib Granted Breakthrough Therapy Designation For Advanced Or Metastatic Non-Small... Dec 8, 2020 - Amgen (NASDAQ: AMGN) today announced that the U.S. Food and Drug Administration (FDA) granted Breakthrough Therapy designation for its investigational KRASG12C... https://www.amgen.com/newsroom/press-releases/2021/02/fda-grants-sotorasib-priority-review-designation-for-the-treatment-of-patients-with-kras-g12c-mutated-locally-advanced-or-metastatic-non-small-cell-lung-cancer FDA Grants Sotorasib Priority Review Designation For The Treatment Of Patients With KRAS... https://www.biospace.com/novel-kras-p-g12c-inhibitor-sotorasib-from-amgen-is-the-frontrunner-for-first-fda-approval-in-advanced-non-small-cell-lung-cancer Novel KRAS p.G12C inhibitor Sotorasib from Amgen is the Frontrunner for First FDA Approval in... Feb 12, 2021 - The novel mutant KRAS p.G12C inhibitor sotorasib developed by Amgen (AMGN) has demonstrated a high response rate and prolonged progression-free survival in... https://www.cancerresearchuk.org/about-cancer/treatment/drugs/sotorasib Sotorasib (Lumykras) | Cancer information | Cancer Research UK Sotorasib is a targeted cancer drug for the treatment of non small cell lung cancer (NSCLC). Find out about how you have it, possible side effects and other... cancer information sotorasib lumykras research uk https://www.cancerresearchuk.org/about-cancer/find-a-clinical-trial/a-trial-looking-at-bay-3498264-and-sotorasib-for-solid-cancers-that-have-spread A trial looking at BAY 3498264 and sotorasib for solid cancers that have spread This trial is looking at adding a new drug called BAY 3498264 to sotorasib for solid cancers. https://www.mdanderson.org/newsroom/kras-inhibitor-sotorasib-shows-meaningful-activity-pancreatic-cancer.h00-159545268.html Sotorasib shows clinically meaningful activity in KRAS G12C-mutated advanced pancreatic cancer | UT... In the Phase I/II CodeBreaK 100 trial, the KRAS G12C inhibitor sotorasib achieved meaningful anticancer activity with an acceptable safety profile in heavily... https://www.lung.org/research/clinical-trials/find-a-clinical-trial/rmc-4630-sotorasib-combo-lung-cancer Phase 2, Open-Label, Study of the Combination of RMC-4630 and Sotorasib for Non-Small Cell Lung... The purpose of this study is to evaluate the antitumor effects of sotorasib and RMC-4630 subjects with KRASG12C mutant NSCLC that have not been exposed to... https://www.lumakras.com/ NSCLC and mCRC Treatment | LUMAKRAS® (sotorasib) nsclc mcrc treatment sotorasib https://alxuranium.com/ Sotorasib Ras inhibitor sotorasib inhibitor